Selected Approaches to Disrupting Protein-Protein Interactions within the MAPK/RAS Pathway

Within the MAPK/RAS pathway, there exists a plethora of protein-protein interactions (PPIs). For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes to provide much needed therapies for patients with KRAS-mutant driven cancers. In this review, we focus on recent strategies to inhibit RAS-signaling via disrupting PPIs associated with SOS1, RAF, PDE delta, Grb2, and RAS.

Automated summary

This review focuses on recent strategies to inhibit RAS-signaling by disrupting protein-protein interactions (PPIs) associated with SOS1, RAF, PDE delta, Grb2, and RAS, in hopes to provide therapies for patients with KRAS-mutant driven cancers.